STAT3 and hepatocellular carcinoma: The combination of sorafenib and YC-1 (a soluble guanylyl cyclase activator) significantly displayed an anti-HCC effect compared with sorafenib or YC-1 used alone by modulating SHP-1/p-STAT3 pathway [106].